101,648 Shares in Core Laboratories Inc. $CLB Purchased by Rice Hall James & Associates LLC
Rice Hall James & Associates LLC recently purchased 101,648 shares of Core Laboratories Inc. (NYSE:CLB), valued at approximately $1.18 million, representing 0.22% of the company. Core Laboratories reported Q2 EPS of $0.11, beating estimates, but revenue missed expectations, while institutional investors now own 97.81% of the company. Analysts currently have a "Moderate Buy" rating for CLB with a $21 target price, significantly higher than its recent trading price of $12.45.
Renaissance Technologies LLC Sells 132,797 Shares of Core Laboratories Inc. $CLB
Renaissance Technologies LLC significantly reduced its stake in Core Laboratories Inc. by 72.4% in Q1 2026, selling 132,797 shares. Despite this institutional sell-off, Core Laboratories reported exceeding Q1 EPS expectations, and CEO Lawrence Bruno increased his personal holdings in the company. Analyst sentiment for Core Laboratories has also improved, with an upgrade to "buy" and a consensus target price of $21.00.
Disciplined Growth Investors (CLB) reports 6.6% Core Laboratories stake on Schedule 13G/A
Disciplined Growth Investors, Inc. has reported a 6.6% beneficial ownership stake in Core Laboratories Inc. (CLB) through a Schedule 13G/A filing. The firm beneficially owns 3,042,177 common shares, holding sole voting power over 2,961,959 shares and sole dispositive power over all 3,042,177 shares. This indicates a significant institutional investment with controlled voting and dispositive rights.
Ariel Investments (CLB) discloses 30.5% Core Laboratories stake in Schedule 13G/A
Ariel Investments, LLC has disclosed a significant stake in Core Laboratories Inc. common stock through a Schedule 13G/A filing. The investment firm beneficially owns 14,074,945 shares, which accounts for 30.5% of the outstanding common stock as of June 30, 2026. This includes sole voting power over 13,141,081 shares and sole dispositive power over all 14,074,945 shares, with Ariel Fund specifically holding 6,474,663 shares.
Core Laboratories (NYSE:CLB) Stock Rating Upgraded by Johnson Rice
Johnson Rice upgraded Core Laboratories (NYSE:CLB) from a "hold" to a "buy" rating, setting a $21.00 price target. This upgrade implies a significant upside, although the broader analyst consensus remains "Hold." The company recently reported better-than-expected EPS but missed revenue estimates, while its CEO and institutional investors have shown confidence through stock purchases and substantial ownership.
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories (NYSE:CLB) recently reported weak earnings, which did not significantly impact its stock price. An analysis suggests that the company's profit was boosted by US$7.1 million in unusual items in the last year, raising concerns that future profits may be weaker without these non-recurring contributions. Investors are cautioned to look beyond the statutory earnings and consider underlying weaknesses, as well as risks facing the company.
Core Laboratories (CLB) Q2 2026 Earnings Call Transcript
Core Laboratories (CLB) reported Q2 2026 earnings, showing 2% sequential revenue growth driven by increased demand for completion products, despite ongoing geopolitical conflicts in the Middle East and Russia/Ukraine impacting its Reservoir Description segment. The company highlighted improved Production Enhancement operating margins due to higher product sales and resolved tax matters, while also maintaining a commitment to shareholder returns through dividends and share repurchases. Core Labs provided Q3 2026 guidance projecting continued sequential revenue growth, primarily from international markets outside the conflict zones.
Core Laboratories N.V. (CLB) stock price, news, quote and history
This Yahoo Finance page provides comprehensive financial data for Core Laboratories N.V. (CLB), including its current stock price, dividend information, key statistics, historical data, and analyst insights. It details the company's business segments—Reservoir Description and Production Enhancement—which serve the oil and gas industry, and offers performance comparisons against the S&P 500. The page also presents earnings trends, valuation measures, and a list of comparable companies in the Oil & Gas Equipment & Services sector.
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories' recent earnings report, despite weak numbers, did not cause significant stock movement. The analysis suggests that the company's profit was boosted by US$7.1m in unusual items, implying that statutory profits might be better than its underlying earnings power. Investors are advised to consider these underlying weaknesses and other factors like margins, growth forecasts, and return on investment.
Core Laboratories' (NYSE:CLB) Weak Earnings May Only Reveal A Part Of The Whole Picture
Core Laboratories Inc.'s recent weak earnings report did not significantly impact its stock movement, but an analysis suggests underlying weaknesses beyond soft profit numbers. The company's profit was boosted by US$7.1 million in unusual items, which are typically not repeated, potentially leading to weaker profits next year. Investors are advised to consider these factors when evaluating the company's true earnings power.
Core Laboratories Inc (CLB) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Core Laboratories Inc (CLB), noting its current earnings forecast score of 6.00 and an average price target of $14.00 based on three analysts. It highlights an expected revenue of $131.33M for the next quarter and an anticipated EPS of $0.15. The analyst consensus is a "Hold" rating for the stock.
Dimensional Fund Advisors LP Increases Stock Position in Core Laboratories Inc. $CLB
Dimensional Fund Advisors LP has increased its stake in Core Laboratories Inc. (NYSE:CLB) by 10.0% in the first quarter, now owning 1,352,329 shares valued at $22,705,000. Other institutional investors like MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd., American Century Companies Inc., and Quantbot Technologies LP have also adjusted their positions in the oil and gas company. The article also details Core Laboratories' recent financial performance, dividend announcement, insider buying activity by CEO Lawrence Bruno, and current analyst ratings.
Core Laboratories Inc. (CLB) Stock Price, News, Quote & History
This article provides a comprehensive overview of Core Laboratories Inc. (CLB), including its current stock price, recent news like its dividend announcement, and detailed financial data. It covers company performance metrics, analyst ratings, and an in-depth profile of its operations in the oil and gas equipment and services sector. The information aims to offer potential investors a clear picture of CLB's market position and financial health.
BlackRock (CLB holder) discloses 8.3% beneficial stake in Core Laboratories Inc
BlackRock, Inc. has filed an amended Schedule 13G, disclosing an 8.3% beneficial ownership in Core Laboratories Inc (CLB). This stake amounts to 3,811,390 shares, with BlackRock holding sole voting power over 3,703,577 shares and sole dispositive power over all 3,811,390 shares. No single BlackRock client holds more than five percent of Core Laboratories' outstanding common stock.
Core Laboratories (NYSE: CLB) CEO purchases 5,000 shares in open-market trade
Core Laboratories Inc. (NYSE: CLB) Chairman and CEO Bruno Lawrence purchased 5,000 shares of the company's common stock on July 31, 2026, at a price of $10.78 per share in an open-market transaction. This purchase increased his direct holdings to 262,438 shares. The Form 4 filing indicates that no Rule 10b5-1 trading plan was associated with this transaction.
Core Laboratories (NYSE:CLB) CEO Lawrence Bruno Buys 5,000 Shares
Core Laboratories CEO Lawrence Bruno recently purchased 5,000 shares of the company's stock for $53,900, increasing his total ownership to 262,438 shares. This insider buying comes as the company reported Q2 EPS of $0.11, surpassing estimates, though revenue declined by 4.3% year-over-year. Core Laboratories also declared a quarterly dividend of $0.01 per share, while analysts maintain a "Reduce" consensus rating on the stock.
CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Core Laboratories Inc. reported its second quarter 2026 results, with revenue of $124.6 million, a 2% sequential increase, and GAAP EPS of $0.13. The company highlighted sequential improvements despite geopolitical conflicts impacting its Reservoir Description segment. Core Lab also announced a quarterly dividend and repurchased shares, while projecting sequential revenue growth for the third quarter of 2026.
Core Laboratories Q2 Earnings Beat Estimates, Decline Y/Y
Core Laboratories (CLB) reported Q2 2026 adjusted earnings of 11 cents per share, surpassing estimates but declining year-over-year due to underperformance in the Reservoir Description segment and increased costs. Revenues of $124.6 million missed estimates and decreased from the previous year, attributed to geopolitical conflicts impacting energy infrastructure and demand for international laboratory services. Despite the decline, the Production Enhancement segment showed strength, and the company repurchased shares while maintaining a low debt leverage ratio.
Q2 2026 Core Laboratories Inc Earnings Call Transcript
Core Laboratories Inc (CLB) reported mixed results for Q2 2026, with production enhancement revenue increasing by 15% sequentially and 5% year-over-year due to international reservoir characterization projects and proprietary perforating technology. However, reservoir description revenue declined by 4% sequentially and 9% year-over-year, impacted by geopolitical disruptions in the Middle East and expanded sanctions in Russia and Ukraine. The company continued its share repurchase program, buying back over 214,000 shares, and generated $3.1 million in free cash flow, while providing a wide revenue guidance range for Q3 2026 due to ongoing geopolitical uncertainties.
Core Laboratories Q2 Earnings Call Highlights
Core Laboratories reported Q2 2026 revenue of $124.6 million, a 2% increase sequentially but a 4% decrease year-over-year, impacted by Middle East and Russia-Ukraine conflicts. The company's CEO, Larry Bruno, highlighted investments in new technologies and improving conditions outside conflict zones, particularly in Production Enhancement. Despite geopolitical challenges affecting its Reservoir Description segment, Core Lab saw increased energetic product sales and expects sequential growth in Q3.
Core Laboratories Inc. /DE/ Q2 2026: Revenue $124.6M, EPS $0.12— 10-Q Summary
Core Laboratories Inc. /DE/ reported its Q2 2026 financial results with revenue of $124.6 million, marking a 4% year-over-year decrease from $130.2 million in Q2 2025. Diluted earnings per share dropped to $0.12 from $0.23 in the prior year, primarily due to weaker international activity, lower equipment shipments, and disruptions from Middle East conflicts and sanctions. Despite overall declines, the company saw growth in U.S. onshore product sales and well diagnostic services, and continued efforts in carbon capture and geothermal projects.
Core Laboratories: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Core Laboratories' Q2, but contains no actual financial details or article content beyond the headline. The body of the article is empty, indicating a placeholder or an article that failed to load content.
Press Release: CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Core Laboratories (NYSE: CLB) announced its second quarter 2026 results. The company reported a revenue of $133.0 million, with a net income of $12.3 million and diluted earnings per share (EPS) of $0.26. Core Lab's CEO, Christopher Hill, highlighted the company's strong financial performance driven by increased demand for its services and products, particularly in international and offshore markets.
Core Laboratories Inc. (NYSE:CLB) Declares $0.01 Quarterly Dividend
Core Laboratories Inc. (NYSE:CLB) announced a quarterly dividend of $0.01 per share, payable on August 31st. The company reported second-quarter EPS of $0.11, exceeding analyst estimates, but revenue declined year-over-year. Despite the earnings beat, the stock traded down 7.7% near its 52-week low, influenced by cautious third-quarter guidance and overall declining annual results.
Core Lab Q2 earnings miss analyst estimates
Core Laboratories Inc. (NYSE:CLB) reported Q2 results that missed analyst expectations, with adjusted EPS of $0.13 against a $0.30 consensus. Revenue was $124.6 million, showing sequential improvement but a year-over-year decline, largely due to geopolitical conflicts impacting its Reservoir Description segment. Despite the miss, the company provided Q3 2026 guidance with anticipated sequential improvements in revenue and EPS.
Core Laboratories Inc (CLB) Institutional Confidence
Core Laboratories Inc (CLB) has an institutional shareholding score of 10.00, placing it first in its industry. The institutional shareholding proportion is 111.85%, reflecting a quarterly decrease of 9.75%. Bill Nygren of OAKMX is the largest institutional shareholder, holding 15.76M shares, which represents 28.60% of outstanding shares.
Core Laboratories (CLB) Q2 Earnings Surpass Estimates
Core Laboratories (CLB) reported Q2 earnings of $0.11 per share, exceeding the Zacks Consensus Estimate of $0.08 per share, marking a 37.50% surprise. Despite the earnings beat, the company's revenues of $124.61 million missed estimates and were down from the previous year. The stock has underperformed the market year-to-date, and based on unfavorable estimate revisions, currently holds a Zacks Rank #4 (Sell).
Core Laboratories (NYSE:CLB) Releases Q3 2026 Earnings Guidance
Core Laboratories (NYSE:CLB) has released its Q3 2026 earnings guidance, projecting EPS between $0.12 and $0.20 and revenue between $128.5 million and $135.5 million, generally aligning with analyst consensus. The stock fell sharply to $9.87, near its 12-month low, on high trading volume, reflecting cautious analyst sentiment with "Reduce" or "Sell" ratings from several firms. Institutional investors have recently adjusted their holdings in the company.
Core Laboratories: Q2 Earnings Snapshot
This article is an earnings snapshot for Core Laboratories' Q2, but the content provided is empty except for a privacy message. No financial results or company details are available in the given text.
Core Laboratories: Q2 Earnings Snapshot
This article provides a brief snapshot of Core Laboratories' Q2 earnings. Without further details, it indicates a concise update regarding their financial performance for the second quarter.
CORE LAB REPORTS SECOND QUARTER 2026 RESULTS
Core Laboratories Inc. reported second-quarter 2026 revenue of $124.6 million, a 2% sequential increase, despite geopolitical conflicts impacting its Reservoir Description segment. The company's operating income rose 42% sequentially, and it repurchased 214,712 shares while announcing a quarterly dividend. Core Lab provided Q3 2026 guidance, expecting continued sequential revenue growth and improved EPS, despite ongoing international headwinds.
Core Laboratories Inc. Approves Cash Dividend, Payable on August 31, 2026
Core Laboratories Inc. announced on July 29, 2026, that its Board of Directors approved a cash dividend of $0.01 per share of common stock. The dividend is scheduled to be paid on August 31, 2026, to shareholders who are on record by August 10, 2026.
Core Laboratories: Q2 Earnings Snapshot
This article provides a brief earnings snapshot for Core Laboratories for its second quarter. While the article title suggests the content would detail the Q2 earnings, the actual content is missing or was not provided in the input.
Core Laboratories Inc (CLB) Financial Health: Profitability & Balance Sheet Analysis
Core Laboratories Inc (CLB) currently holds a financial score of 6.00, placing it 138th out of 160 in the Professional & Commercial Services industry, indicating stable financial health with average operating efficiency. The company recently reported a quarterly revenue of $121.80M, down 1.45% year-over-year, and a net profit decrease of 412.34% year-over-year. Key metrics for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns showed varying scores.
Core Laboratories (NYSE: CLB) posts Q2 profit, buybacks and Q3 guidance
Core Laboratories (NYSE: CLB) reported Q2 2026 revenue of $124.6 million, up 2.3% sequentially but down 4.3% year-over-year, with diluted EPS of $0.13. The company repurchased 214,712 shares for $2.7 million and declared a quarterly dividend of $0.01 per share. For Q3 2026, Core Lab projects revenue between $128.5 million and $135.5 million and EPS between $0.12 and $0.20, anticipating sequential improvement despite ongoing geopolitical conflicts.
Core Laboratories Inc (CLB) Cash Flow
This article provides a comprehensive overview of Core Laboratories Inc.'s (CLB) cash flow statement, including operating, investing, and financing cash flows, presented in a quarterly and annual format. It details various components such as net income, capital expenditures, and debt transactions, enabling evaluation of the company's financial health. The page also includes FAQs defining different cash flow types and their significance for CLB.
Core Laboratories Inc (CLB) Income Statement
This article provides the quarterly and annual income statements for Core Laboratories Inc (CLB), detailing its financial performance and operational efficiency. It presents data for various financial metrics over several years and quarters, including total revenue, operating expenses, and net income, alongside year-over-year percentage changes. The content also includes FAQs explaining how to interpret the income statement and defining key financial terms.
CLB|Core Laboratories Inc|Price:11.670|Chg%:-0.120
This article provides a detailed financial overview of Core Laboratories Inc (CLB), including its latest stock price, market capitalization, and P/E ratio. It presents a comprehensive data dashboard with quarterly and annual financial statements such as income statements, balance sheets, and cash flow statements. The report also includes upcoming earnings information, analyst ratings (HOLD), and answers to frequently asked questions regarding the company's financial metrics for FY2025.
Core Laboratories Inc (CLB) Earnings Forecast: Future EPS & Revenue Growth Estimates
This article provides an earnings forecast for Core Laboratories Inc (CLB), noting its current earnings forecast score of 6.00 and ranking in the Professional & Commercial Services industry. It details analyst ratings, price targets, and historical and forecasted EPS and revenue figures. Key financial metrics and frequently asked questions about CLB's outlook are also included.
Core Laboratories Inc (CLB) Technical Analysis: Support, Resistance, Indicators & Moving Averages
This article provides a technical analysis of Core Laboratories Inc (CLB), detailing its price momentum score of 3.60 within the Professional & Commercial Services industry. It highlights the stock's current trading range between a resistance level of 12.44 and a support level of 10.74. The analysis also includes detailed technical indicators such as MACD, RSI, and moving averages, concluding with a neutral signal based on these metrics.
Core Laboratories Inc (CLB) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed breakdown of Core Laboratories Inc (CLB) revenue by business segment and geographical region. It shows that the company's revenue is primarily driven by service sales, accounting for 75.86% of the total, with product sales making up the remaining 24.14%. Geographically, the majority of revenue (66.70%) comes from countries outside the United States, with the US contributing 33.30%.
CLB|Core Laboratories Inc|Price:11.690|Chg%:-0.110
Core Laboratories Inc. (CLB) currently trades at $11.67, experiencing a 1.02% decrease as of July 24, 2026. The company, which specializes in reservoir description and production enhancement services for the oil and gas industry, is considered fairly valued with healthy fundamentals and high growth potential, despite a forecasted downward trend in the medium term. Analyst ratings for CLB are predominantly "Hold," with a target price of $15.50, suggesting a potential upside of 35.85%.
What's in Store for Core Laboratories Stock in Q2 Earnings?
Core Laboratories Inc. (CLB) is preparing to release its second-quarter 2026 earnings on July 29, with analysts projecting a profit of 8 cents per share on revenues of $127.56 million. Despite benefits from international projects and an asset-light model, the company faces potential headwinds from increased operating expenses and a projected decline in overall revenues, primarily due to its Reservoir Description segment. The Zacks model currently indicates that CLB is unlikely to post an earnings beat this quarter, classifying it with a Zacks Rank #4 (Sell).
What's in Store for Core Laboratories Stock in Q2 Earnings?
Core Laboratories (CLB) is scheduled to release its Q2 2026 earnings on July 29, with the Zacks Consensus Estimate projecting a profit of 8 cents per share on revenues of $127.56 million. Despite expected benefits from resilient international projects and an asset-light business model, total revenues are anticipated to decline year-over-year due to potential decreases in the Reservoir Description segment and increased operating expenses. The Zacks model does not conclusively predict an earnings beat for CLB, which currently holds a Zacks Rank #4 (Sell).
Core Laboratories (NYSE:CLB) Trading Up 5.9% - Here's What Happened
Core Laboratories (NYSE:CLB) saw its stock price increase by 5.9% in mid-day trading on Wednesday, though trading volume was lighter than usual. This rise occurred despite recent downgrades from analysts at Weiss Ratings and Wall Street Zen, both issuing "Sell" ratings, resulting in a consensus "Reduce" rating from MarketBeat. The company's first-quarter earnings met estimates, but revenue slightly missed expectations and fell year-over-year, and it recently paid a low quarterly dividend.
Earnings Preview: Core Laboratories (CLB) Q2 Earnings Expected to Decline
Core Laboratories (CLB) is expected to report a year-over-year decline in Q2 earnings and revenues. The company's Earnings ESP (Expected Surprise Prediction) currently stands at +6.67%, suggesting a potential earnings beat, though its Zacks Rank of #4 (Sell) complicates a definitive prediction. Investors are advised to consider other factors beyond just the earnings beat or miss.
Core Laboratories (CLB) Expected to Release Earnings on Wednesday
Core Laboratories (CLB) is scheduled to release its Q2 2026 earnings after market close on Wednesday, July 29th, with analysts expecting $0.08 EPS on $126.26 million in revenue. The company’s own guidance ranges from $0.06 to $0.12 EPS. CLB stock has faced recent pressure, trading around $11.48, and has received "sell" ratings from some analysts, leading to a consensus "Reduce" rating.
Heartland Advisors Inc. Makes New $2.52 Million Investment in Core Laboratories Inc. $CLB
Heartland Advisors Inc. recently purchased a new stake of 150,000 shares in Core Laboratories Inc. valued at approximately $2.52 million. This investment comes amid other institutional adjustments, with the company maintaining high institutional ownership at 97.81%. However, recent analyst sentiment has turned negative, with Weiss Ratings and Wall Street Zen downgrading the stock to a "Sell" rating, resulting in an average "Reduce" rating for Core Laboratories.
Price to sales forward of Core Laboratories Inc. – NYSE:CLB
The article provides a financial metric, "Price to sales forward," for Core Laboratories Inc. (NYSE: CLB). It is presented on the TradingView platform, typically used for stock market analysis. The content is very minimal, essentially just stating the metric and the company name.
Price to sales forward of Core Laboratories Inc. – FWB:HJ1
This article displays the "Price to sales forward" metric for Core Laboratories Inc. (FWB:HJ1) as presented on TradingView. It indicates that the market for this stock was closed and no trades had occurred. The content primarily shows navigation elements and disclaimers related to data providers and copyrights.
